No Data
KPC Pharmaceuticals' Unit Gets Nod to Add Indications for Colchicine Tablets
KPC Pharmaceuticals Gets China Clinical Trial Approval for Fatty Liver Drug
kpc pharmaceuticals, inc. (600422.SH): Received a notice of approval for drug clinical trials.
Gelonghui November 22nd | kpc pharmaceuticals, inc. (600422.SH) announced that the company recently received the KPC000154 tablet issued by the State Food and Drug Administration (Notice Number: 2024LP02631, 2024LP02632, hereinafter referred to as "the new drug") in accordance with the Category 1 New Drug Acceptance "Drug Clinical Trial Approval Notice", allowing the new drug to conduct related clinical trials. Research, KPC000154 tablets for the treatment of Nonalcoholic steatohepatitis (NASH).
chinares pharma (03320): china resources sanjiu medical & pharmaceutical (000999.SZ) will sell 51% of its stake in Kunshan Pharmaceutical (600422.SH).
Chinares pharma (03320) issued an announcement that on November 21, 2024, china resources sanjiu medical & pharmaceutical and Kunming Pharma entered into a share transfer agreement...
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
The Three-year Decline in Earnings for KPC PharmaceuticalsInc SHSE:600422) Isn't Encouraging, but Shareholders Are Still up 82% Over That Period
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing
